Last updated: August 4, 2025
Introduction
China Patent CN103079544, granted in 2013, pertains to a novel pharmaceutical invention aiming to enhance drug efficacy, stability, or delivery. As patent landscapes evolve rapidly within China's burgeoning pharmaceutical sector, comprehensive understanding of the patent's scope and claims is crucial for stakeholders—pharmaceutical companies, researchers, and legal professionals—to navigate innovation pipelines, competitive intelligence, and strategic patenting decisions.
Patent Overview
Title: Likely related to a pharmaceutical composition, compound, or delivery system (exact details depend on the original patent document).
Application Filing Date: 2011 (approximate, based on original publication).
Publication Date: 2012
Grant Date: 2013
This patent is positioned within China's rapid-growing drug patent infrastructure, fostering innovation especially in the areas of traditional Chinese medicine (TCM), chemical drugs, and biopharmaceuticals.
Scope of the Patent
CN103079544 primarily claims a specific pharmaceutical composition, process, or compound with defined therapeutic use or improved efficacy. The scope reflects a strategic effort to secure exclusive rights over:
- A novel chemical entity or a derivative thereof.
- A unique formulation or drug delivery system.
- A manufacturing process optimizing yield, purity, or stability.
- Therapeutic application for particular indications.
The patent’s scope is anchored in the inventive step of its core compound or formulation, which is demonstrated through problem-solution arguments distinguishing it from prior art.
Key Elements of the Scope:
- Chemical Structure & Composition: The patent likely claims a specific molecular structure with defined substituents, which confers unique pharmacological properties.
- Method of Production: Specific process parameters or techniques enhancing efficiency and purity.
- Formulation & Delivery: Possibly claims related to sustained-release matrices, targeted delivery, or stabilization methods.
- Therapeutic Use: Claims may extend over specific medical indications, asserting the compound’s efficacy in, e.g., anti-inflammatory, anti-tumor, or metabolic disorders.
The scope's breadth varies, potentially encompassing broad composition claims or narrower process claims, contingent on the patent draft's strategic scope.
Analysis of Patent Claims
Claim Structuring:
The typical structure hinges upon independent claims defining the core invention, supported by dependent claims elaborating on specific embodiments.
Independent Claims:
- Usually claim a chemical compound or composition with structural specifics.
- May claim methods of preparing the compound.
- Could encompass therapeutic methods using the compound.
Dependent Claims:
- Specify pharmacological properties, dosage forms, administration routes, and combinations with other agents.
- Cover specific substituents, salts, or analogs.
Claim Breadth and Validity:
- Broader claims enhance patent value but face higher invalidity risks if overly generic.
- Narrow claims improve enforceability but may limit commercial scope.
Patent Claim Analysis:
- The core structural claims protect the chemical entity.
- The formulation claims safeguard specific drug delivery systems.
- Process claims ensure protection even if core compounds are neutralized by prior art, provided manufacturing techniques are novel.
Potential Vulnerabilities:
- Overlap with existing patents in the same class or mechanism.
- Insufficient inventive step if similar compounds or processes exist.
- Obviousness of modifications based on prior art.
Patent Landscape in China for CN103079544
1. Innovator Activity and Filing Trends
Chinese pharmaceutical patent activity in this domain has surged, driven by government initiatives promoting innovation (e.g., ‘Made in China 2025’), with filing volumes reaching hundreds annually. CN103079544 contributed to the strategic patenting efforts aimed at securing core assets for specific therapeutic classes.
2. Competitor Patent Activity
Major Chinese pharma institutions such as Sinopharm, China National Pharmaceutical Group (CNPG), and university-affiliated research institutes actively file similar patents, targeting same or overlapping indications, with incremental innovations or alternate formulations.
3. Legal and Market Landscape
- The Chinese patent examination system emphasizes inventiveness and novelty, leading to rapid patent grants for truly inventive compounds.
- Patent expiry timelines are typically 20 years from filing, influencing R&D timelines.
- Compulsory licensing or patent challenges are relatively less prevalent but gaining attention as local generics expand via patent challenges.
4. International Patent Considerations
While CN103079544 is scoped for China, patent families often extend protection to markets such as the US and EU. Cross-jurisdictional patent applications (e.g., PCT filings) are likely to encompass this invention, ensuring comprehensive global protection.
Implications for Stakeholders
- For Innovators: The patent demonstrates a method or composite that may serve as a foundation for further R&D, though assessing freedom-to-operate requires detailed prior art analysis.
- For Generic Manufacturers: The scope’s breadth informs potential patent infringement risks when developing similar drugs; narrow claims afford opportunities for designing around.
- For Patent Holders: Maintaining patent robustness against challenges involves ongoing patent amendment strategies and ancillary patent filing (e.g., method claims or new formulations).
Conclusion
China Patent CN103079544 embodies a strategic innovation with potentially broad claims over a pharmaceutical compound or formulation, aimed at establishing monopoly rights within China’s dynamic pharmaceutical market. Its claim architecture emphasizes core structures, methods, or uses, with a landscape characterized by aggressive patenting activities and intense competition.
Ensuring comprehensive patent protection entails continuous monitoring of similar applications, understanding the scope limitations, and exploring avenues to strengthen or expand claims, especially if preparing for multinational patent families.
Key Takeaways
- Strategic Claim Scope: Focus on defining core inventive features while balancing breadth to maximize enforceability.
- Landscape Awareness: Chinese patent activity in pharmaceuticals is highly competitive; monitoring similar filings is essential.
- Global Consideration: For international expansion, file corresponding patent applications, particularly via PCT or direct filings.
- Patent Maintenance: Regularly assess patent enforceability and consider supplementary patent filings to protect incremental innovations.
- Legal Vigilance: Be vigilant regarding patent validity challenges and potential infringement risks; consider licensing or cross-licensing strategies.
FAQs
-
What is the primary inventive feature protected by China patent CN103079544?
The patent primarily claims a specific chemical compound or formulation exhibiting enhanced stability or therapeutic efficacy, with specific structural or process features that distinguish it from prior art.
-
How broad are the claims in this patent?
The claims range from specific compounds and formulations to methods of preparation and use, with the breadth depending on the strategic drafting to balance exclusivity and validity.
-
Can this patent be challenged or invalidated?
Yes. Common grounds include lack of novelty, obviousness, or insufficient inventive step. Prior art searches are crucial in assessing robustness.
-
What is the patent landscape in China like for pharmaceutical patents similar to CN103079544?
It is highly active, with multiple filings by domestic and international entities, especially in areas like chemical drugs, biologics, and delivery systems, leading to a competitive environment.
-
Should companies seek patent protection beyond China for similar inventions?
Yes. To maximize market coverage and safeguard investments, patent filings in jurisdictions like the US, EU, or existing PCT applications are recommended, especially for blockbuster drugs.
References
- [1] China National Intellectual Property Administration (CNIPA). Patent CN103079544.
- [2] WIPO PCT Database.
- [3] Market analysis reports on China's pharmaceutical patent filings.
- [4] Patent landscape reports from Chinese patent authorities.
